Insilico Medicine Advances Parkinson’s Therapy with IND-Enabling Milestone for AI-Driven Oral NLRP3 Inhibitor ISM8969
Cambridge, MA – August 14, 2025 – Insilico Medicine, a pioneering clinical-stage biotech company harnessing the power of generative artificial ...
